Jefferies Raising Price Target On Insulet Corp (PODD)

Jefferies & Co. is raising its price target on shares of Insulet Corp PODD to $20 from $19, and has a Buy rating on shares. In a note to clients, Jefferies writes, "Insulet reported solid 4Q results this evening with revenues of $27.8mn matching forecasts. The company updated the regulatory path for the next gen pod with the FDA no longer requiring a clinical trial. A submission is expected in early 2Q." Shares of PODD lost 21 cents yesterday to close at $17.64, a loss of 1.2%.